Method of preventing or reducing eosinophilia
CA 2002144 C · Owner: Dnax Research Institute Of Molecular And Cellular Biology Inc. · Inventors: Rennick, Donna M.; Coffman, Robert L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of preventing or reducing eosinophilia associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-5. Preferably the, antagonist is a blocking monoclonal antibody specific for human interleukin-5, or a fragment or binding composition derived therefrom.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 2, 1989 and granted March 28, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 2, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 2, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.